Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA

NCT01015352 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT01015352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01015352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
March 31, 2014
Enrollment
98 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes